Table 1 The association between the expression of AHR and cytochromes and the clinicopathological features in BC patients. Data were extracted from the GSE13507 dataset
Parameters | n | AHR | P | CYP1A1 | P | CYP1A2 | P | CYP1B1 | P | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Low (%) | High (%) | Low (%) | High (%) | Low (%) | High (%) | Low (%) | High (%) | ||||||
Gender | |||||||||||||
Female | 30 | 05 (16.7) | 25 (83.3) | 0.149 | 26 (86.7) | 4 (13.3) | 0.079 | 27 (90.0) | 03 (10.0) | 0.525 | 21 (70.0) | 09 (30.0) | 0.060 |
Male | 135 | 40 (29.6) | 95 (70.4) | 96 (71.1) | 39 (28.9) | 126 (93.3) | 09 (6.7) | 69 (51.1) | 66 (48.9) | ||||
Age (years) | |||||||||||||
≤65 | 69 | 18 (26.1) | 51 (73.9) | 0.772 | 50 (72.5) | 19 (27.5) | 0.714 | 66 (95.7) | 03 (4.3) | 0.220 | 30 (43.5) | 39 (56.5) | 0.016* |
> 65 | 96 | 27 (28.1) | 69 (71.9) | 72 (75.0) | 24 (27.5) | 87 (90.6) | 09 (9.4) | 60 (62.5) | 36 (37.5) | ||||
Hist. Grade | |||||||||||||
Low | 105 | 31 (29.5) | 74 (70.5) | 0.390 | 83 (79.0) | 22 (21.0) | 0.048* | 101 (96.2) | 04 (3.8) | 0.023* | 60 (57.1) | 45 (42.9) | 0.375 |
High | 60 | 14 (23.3) | 46 (76.7) | 39 (65.0) | 21 (35.0) | 52 (86.7) | 08 (13.3) | 30 (50.0) | 30 (50.0) | ||||
Stage | |||||||||||||
Ta-T1 | 104 | 32 (30.8) | 72 (69.2) | 0.188 | 94 (90.4) | 10 (9.6) | 0.005* | 100 (96.2) | 04 (3.8) | 0.027* | 65 (62.5) | 39 (37.5) | 0.007* |
>T2 | 61 | 13 (21.3) | 48 (78.7) | 45 (73.8) | 16 (26.2) | 53 (86.9) | 08 (13.1) | 25 (41.0) | 36 (59.0) | ||||
Progression | |||||||||||||
No | 134 | 40 (29.9) | 94 (70.1) | 0.122 | 104 (77.6) | 30 (22.4) | 0.025* | 127 (94.8) | 07 (5.2) | 0.035* | 81 (60.4) | 53 (39.6) | 0.002* |
Yes | 31 | 05 (16.1) | 26 (83.9) | 18 (58.1) | 13 (41.9) | 26 (83.9) | 05 (16.1) | 09 (29.0) | 22 (71.0) | ||||